
Immunogenicity and safety of an E. coli-produced bivalent human papillomavirus (type 16 and 18) vaccine: A randomized controlled phase 2 clinical trial
Keywords: چگالی نوری; Human papillomavirus; Vaccine; Immunogenicity; Safety; Randomized controlled clinical trial; CFDA; Chinese Food and Drug Administration; CIs; confidential intervals; eVLP-based ELISA; E. coli-expressed HPV L1 VLP-based ELISA; GFP; green fluorescent protei